CAPTRUST Financial Advisors
SGTX

CAPTRUST Financial Advisors’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-115
Closed -$1K – 4458
2022
Q2 		$1K Sell
115
-270
-70% -$3.63K ﹤0.01% 4818
2022
Q1 		$7K Buy
+385
New +$8.58K ﹤0.01% 4016

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CAPTRUST Financial Advisors's SGTX Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q3 2022, closing a stake of 115 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in SGTX in Q1 2022 and held it in 2 quarters. The position peaked at $7K in Q1 2022. 33 funds tracked by Wall St. Rank hold SGTX as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 115 Sigilon Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • CAPTRUST Financial Advisors's Sigilon Therapeutics, Inc. Common Stock position peaked at $7K in Q1 2022.
  • 33 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.